

**Supplemental Figure 1. Nintedanib inhibited the PDGFR signalling pathway, the proliferation and the migration of IPF and control HLFs stimulated with PDGF-BB.**

**A,C.** Representative Western blots showing the phosphorylation of PDGFR and ERK in IPF (n=4) and control (n=4) HLFs treated with 0.01-0.3  $\mu$ M nintedanib for 3 h and then stimulated with 25 ng/ml PDGF-BB for 10 min. **B, D.** Protein levels were quantified by densitometry and then normalized to GAPDH levels. The fold change in the levels of phosphorylated proteins found in stimulated cells was compared to that measured in untreated cells, arbitrarily set at 1. **E,G.** For proliferation analysis, IPF (n=6) and control (n=6) HLFs were treated with 0.01-0.3  $\mu$ M nintedanib for 3 h and then stimulated with 50 ng/ml PDGF-BB for 72 h. **The proliferation was determined by fluorescent acridine orange/propidium iodide staining and automated fluorescence cell counting. The relative cell proliferation was calculated by dividing the number of viable cells treated with nintedanib +/- PDGF-BB by the number of viable untreated cells, which was arbitrarily set at 1. F, H.** The migration of IPF (n=9) and control (n=4) HLFs was analysed using a modified-Boyden chamber assay. Cells were treated with 0.01-1  $\mu$ M nintedanib for 24 h along with 25 ng/ml PDGF-BB used as a chemoattractant to induce cell migration. The relative cell migration was calculated by dividing the number of migrating cells treated with nintedanib +/- PDGF-BB by the number of untreated migrating cells, arbitrarily set at 1. Results are expressed as means  $\pm$  SEM of 4-9 independent experiments. Significant differences were determined by ANOVA followed by the Dunnett's multiple comparison t-test (\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ ). NTD: nintedanib

**Supplemental Figure. 2. Nintedanib attenuated the phosphorylation of SMAD2/3 and the expression of myofibroblastic markers in IPF and control HLFs stimulated with TGF- $\beta$ 1.**

**A, C, E, G.** IPF (n=4) and control (n=4) HLFs were treated with 0.01-1  $\mu$ M nintedanib for 3 h and stimulated with 1 ng/ml TGF- $\beta$ 1 for 30 min (**A, E**) or 24 h (**C, G**). Representative

Western blots showing the phosphorylation of SMAD2 and SMAD3 (**A, E**), fibronectin (FN), collagen I (COL1) and  $\alpha$ -SMA (**C, G**). **B, D, F, H**. Protein levels were quantified by densitometry and normalized to the GAPDH levels. The fold change in protein expression in stimulated cells was determined relatively to the protein expression measured in untreated cells, arbitrarily set at 1. Results are expressed as means  $\pm$  SEM of 4 independent experiments. Significant differences were determined ANOVA followed by Dunnett's multiple comparison t-test (\*  $p < 0.05$ ; \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ ). NTD: nintedanib